Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some dosing/bleeding and certain contraindications and adverse reactions align with the provided label excerpts, but multiple safety-relevant areas (notably pregnancy and lactation) are not supported by any supplied label sections, and an active-ingredient/brand-equivalence claim is absent from the provided label excerpts.
Category Scores
Accurate Statements
Camila dosing adherence matters for contraceptive reliability.
DOSAGE AND ADMINISTRATION (must be taken exactly as directed); 2. Efficacy (typical failure rate due to late or omitted pills).
Camila is typically taken as one tablet every day.
DOSAGE AND ADMINISTRATION (One tablet is taken every day, at the same time).
Common progestin-only pill side effects can include changes in bleeding pattern (spotting or irregular periods).
ADVERSE REACTIONS (Menstrual irregularity; Frequent and irregular bleeding are common).
Common progestin-only pill side effects can include nausea.
ADVERSE REACTIONS (Headache, breast tenderness, nausea, and dizziness...).
Common progestin-only pill side effects can include breast tenderness.
ADVERSE REACTIONS (Headache, breast tenderness, nausea, and dizziness...).
Common progestin-only pill side effects can include headaches.
ADVERSE REACTIONS (Headache, breast tenderness, nausea, and dizziness...).
Common progestin-only pill side effects can include acne.
ADVERSE REACTIONS (Androgenic side effects such as acne...).
People with unexplained vaginal bleeding may need to avoid progestin-only contraceptives or get clinician guidance first.
CONTRAINDICATIONS (Undiagnosed abnormal genital bleeding should not be used).
People with certain liver problems may need to avoid progestin-only contraceptives or get clinician guidance first.
CONTRAINDICATIONS (Benign or malignant liver tumors; Acute liver disease).
Norethindrone in Camila is a progestin-only oral contraceptive pill.
WARNINGS (Camila does not contain estrogen and therefore is within the progestin-only oral contraceptive context).
Unsupported Statements
Camila tab 0.35 mg usually refers to tablets containing 0.35 mg (350 micrograms) of norethindrone.
No provided label excerpt identifies Camila as norethindrone 0.35 mg or specifies the active ingredient strength.
Camila is used for people who cannot take estrogen.
The provided label excerpt states Camila does not contain estrogen, but no explicit indication for people who cannot take estrogen is shown in the supplied label sections.
Camila is used for people who prefer a progestin-only option.
No indication phrased as preference-based use is present in the supplied label sections.
Camila is generally considered a brand of the norethindrone 0.35 mg progestin-only pill (often called the minipill).
No provided label excerpt identifies Camila as norethindrone 0.35 mg or calls it a minipill.
Common progestin-only pill side effects can include mood changes.
ADVERSE REACTIONS in the supplied excerpts do not mention mood changes.
People with a history of hormone-sensitive cancers may need to avoid progestin-only contraceptives or get clinician guidance first.
Only breast carcinoma is explicitly listed under contraindications; no general statement about 'hormone-sensitive cancers' appears in the supplied excerpts.
People with severe cardiovascular disease risks may need to avoid progestin-only contraceptives or get clinician guidance first.
The supplied warnings excerpt states the relationship between POPs and heart attack/stroke risk has not been established; no explicit contraindication/guidance for cardiovascular risk is provided in the supplied excerpts.
Progestin-only pills are often used during breastfeeding.
No breastfeeding/lactation information is included in the provided label excerpts.
Contradictions
Important Omissions
Pregnancy-related labeling guidance (e.g., contraindication for known or suspected pregnancy) is not addressed by the evaluated extracted claims set.
Importance:
High
Lactation/breastfeeding-specific labeling information is not addressed by the evaluated extracted claims set.
Importance:
High
Indications and usage details are not provided in the supplied excerpts, and the extracted claims include indication-like statements (birth control; cannot take estrogen; preference) that are not directly supported by the provided INDICATIONS AND USAGE text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several extracted claims align with label-supported contraindications (e.g., undiagnosed abnormal genital bleeding) and adverse reactions (menstrual irregularity, nausea, breast tenderness, headache, acne). However, pregnancy and lactation-specific label content is not supported/covered by the provided excerpts, and some safety-relevant contraindication categories are not explicitly supported (e.g., 'hormone-sensitive cancers', broad cardiovascular risk). These gaps could lead to incomplete label-consistent safety interpretation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Key safety-relevant label areas (pregnancy and lactation) are not supported by the provided label excerpts, and an active-ingredient/brand-equivalence claim is absent from those excerpts.
Suggested Improvement
Limit claims to what is directly supported by the supplied label sections (e.g., daily timing; menstrual irregularity and listed adverse reactions; contraindications explicitly listed). Remove or qualify unsupported claims about active ingredient/brand equivalence, breastfeeding, and broad contraindication categories not explicitly present in the excerpts.